Cedalco

Cedalco is a pre-clinical stage biotechnology company focused on developing small molecule therapeutics that modulate aldehyde dehydrogenase (ALDH) enzymes. The company's primary focus is on ALDH2 activators designed to treat conditions associated with toxic aldehyde accumulation, such as alcohol use disorder and certain genetic diseases like Fanconi anemia. By enhancing the body's natural detoxification pathways, Cedalco aims to mitigate the systemic damage caused by acetaldehyde and other reactive aldehydes. The company is leveraging research into enzyme kinetics and structural biology to optimize its lead candidates for clinical development.